

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Eflornithine maintenance treatment after first-line therapy for high-risk neuroblastoma ID4060

#### Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Norgine (eflornithine)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for Equality</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Childhood Cancer Parents Alliance</li> <li>• Children with Cancer UK</li> <li>• Children’s Cancer and Leukaemia Group</li> <li>• Contact a Family</li> <li>• Genetic Alliance UK</li> <li>• Gene People</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Mitchell’s Miracles</li> <li>• Neuroblastoma UK</li> <li>• Solving Kids’ Cancer UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Teenage Cancer Trust</li> <li>• Tenovus Cancer Care</li> <li>• Together for Shorter Lives</li> <li>• Young Lives vs Cancer</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Institute of Radiology</li> <li>• British Paediatric Neurology Association</li> <li>• British Psychosocial Oncology Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Hospital Information Services – Jehovah’s Witnesses</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association for Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AAH Pharmaceuticals (isotretinoin)</li> <li>• Alliance healthcare (isotretinoin)</li> <li>• Colorama Pharmaceuticals (isotretinoin)</li> <li>• CST Pharma (isotretinoin)</li> <li>• DE Pharmaceuticals (isotretinoin)</li> <li>• Ennogen Healthcare (isotretinoin)</li> <li>• EUSA Pharma (dinutuximab)</li> <li>• Medihealth (isotretinoin)</li> </ul>

Provisional stakeholder list for the single technology appraisal of eflornithine maintenance treatment after first-line therapy for high-risk neuroblastoma ID4060

Issue date: March 2022

© National Institute for Health and Care Excellence 2022. All rights reserved

1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Cancer Research UK</li> <li>• Children’s Cancer and Leukaemia Group</li> <li>• Neonatal &amp; Paediatric Pharmacists Group</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Paediatrics and Child Health</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Coastal West Sussex CCG</li> <li>• NHS Guildford and Waverley CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Roche (isotretinoin)</li> <li>• Sigma Pharmaceuticals (isotretinoin)</li> <li>• Sun Pharmaceutical Industries Europe (isotretinoin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Childhood Cancer Group</li> <li>• Cochrane UK</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.